Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease

Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease

Childhood interstitial lung disease (chILD) comprises >200 rare respiratory disorders, with no currently approved therapies and variable prognosis. Nintedanib reduces the rate of forced vital capacity (FVC) decline in adults with progressive fibrosing interstitial lung diseases (ILDs). We present...

Full description

Bibliographic Details
Main Authors: Robin Deterding, Matthias Griese, Gail Deutsch, David Warburton, Emily M. DeBoer, Steven Cunningham, Annick Clement, Nicolaus Schwerk, Kevin R. Flaherty, Kevin K. Brown, Florian Voss, Ulrike Schmid, Rozsa Schlenker-Herceg, Daniela Verri, Mihaela Dumistracel, Marilisa Schiwek, Susanne Stowasser, Kay Tetzlaff, Emmanuelle Clerisme-Beaty, Lisa R. Young
Format: Article
Language:English
Published: European Respiratory Society 2021-06-01
Series:ERJ Open Research
Online Access:http://openres.ersjournals.com/content/7/2/00805-2020.full

Internet

http://openres.ersjournals.com/content/7/2/00805-2020.full

Similar Items